← Back to Search

Hemostatic Agent

Treatment with XSTAT for Bleeding (PhoXSTAT Trial)

N/A
Waitlist Available
Led By Jan Jansen, MBBS, PhD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through 29 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests the XSTAT® device, which uses expanding sponges to stop bleeding in patients with junctional wounds. The sponges quickly fill the wound and press against bleeding areas to control blood loss.

Eligible Conditions
  • Bleeding
  • Hemorrhagic Shock
  • Penetrating Injury

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through 29 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through 29 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse events from use of XSTAT device
Ease of use of XSTAT device by EMS personnel
Incidence of patients with hemorrhage from junctional wounds
+12 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Treatment with XSTATExperimental Treatment1 Intervention
Participants randomized to the treatment arm will be treated using the study device - XSTAT.
Group II: Standard CareExperimental Treatment1 Intervention
Participants assigned to the control group receive standard prehospital care, consisting of direct pressure/dressings.

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,646 Previous Clinical Trials
2,342,772 Total Patients Enrolled
Jan Jansen, MBBS, PhDPrincipal InvestigatorThe University of Alabama at Birmingham
1 Previous Clinical Trials
1,100 Total Patients Enrolled
~0 spots leftby Nov 2025